Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-AGT01 RVR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-AGT1 RVR | EXPERIMENTAL | Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of zilebesiran followed by a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-AGT01 RVR | DRUG | ALN-AGT01 RVR will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
| Zilebesiran | DRUG | Zilebesiran will be administered SC |
Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
ALN-AGT01 RVR is an investigational medicine being developed by Alnylam Pharmaceuticals, Inc. (ticker ALNY) for the treatment of hypertension. It is currently in Phase 2 clinical development and is being studied in adults with mild to moderate hypertension. It has not been approved by the FDA.
ALN-AGT01 RVR is being studied for the treatment of hypertension, specifically mild to moderate hypertension in adults. The Phase 2 trial enrolls patients aged 18 years and older in the United States. It is an investigational therapy and is not approved for any indication.
ALN-AGT01 RVR is being developed by Alnylam Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ALNY. Alnylam is the sponsor of the ongoing Phase 2 study of the drug in hypertension.
ALN-AGT01 RVR is in Phase 2 clinical development. One Phase 2 trial is currently recruiting, and no trials of the drug have been completed. The program has not reached regulatory approval, so ALN-AGT01 RVR remains an investigational therapy for hypertension.
ALN-AGT01 RVR is being evaluated in the Phase 2 trial NCT07553442, titled A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran. The trial is recruiting in the United States, is placebo-controlled and double-blind, and plans to enroll 93 participants.
No. ALN-AGT01 RVR is an investigational drug in Phase 2 clinical development and has not been approved by the FDA. It is being studied in a single recruiting Phase 2 trial in adults with mild to moderate hypertension.